Annovis Bio Inc. is set to present at Fierce Biotech Week 2026, where CEO Maria Maccecchini will discuss new insights into Alzheimer’s disease. Researchers have long focused on a single protein’s role in Alzheimer’s, but evidence suggests that multiple neurotoxic proteins contribute to the disease. This shift in understanding could lead to more effective treatments for those affected by Alzheimer’s.

For people concerned about aging and cognitive health, this research could be significant. Annovis is developing a new oral therapy called buntanetap, which targets several proteins linked to Alzheimer’s, such as amyloid beta and tau. Early data indicates that this treatment may offer meaningful benefits, potentially improving memory and cognitive function for individuals at risk of or living with Alzheimer’s.

The research is currently in a pivotal Phase 3 clinical trial, which is a critical stage for testing the effectiveness of new treatments in larger groups of people. While the initial results are promising, it’s important to remember that these findings are still under investigation and have not yet been proven in the broader population.

As this research progresses, staying informed about developments in Alzheimer’s treatments could be beneficial for anyone looking to support their brain health as they age. Engaging with the latest findings and considering lifestyle choices that promote cognitive well-being may help you maintain mental clarity and resilience in the long run.

Source: longevity.technology